Senseonics brings on Francine Kaufman as chief medical officer

boardroom
Kaufman has served as head of the Center for Endocrinology, Diabetes and Metabolism at Children’s Hospital Los Angeles, as well as chair of the National Diabetes Education Program. (Pixabay)

Francine Kaufman, former president of the American Diabetes Association and most recently chief medical officer for Medtronic Diabetes, has joined continuous glucose monitor developer Senseonics as its new CMO.

The company hopes the hire will help bolster the U.S. commercialization of its implantable, 90-day Eversense CGM system, which kicked off last summer, as well as support Senseonics’ clinical development and validation efforts.

“Fran is one of the world’s leading endocrinologists and her deep understanding of the global medical, research, and clinical diabetes community coupled with her track record of applying novel technologies to advance diabetes care for patients make her ideally suited for the role,” Senseonics President and CEO Tim Goodnow said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Kaufman’s career as a pediatric endocrinologist has included turns as director of the Comprehensive Childhood Diabetes Center and head of the Center for Endocrinology, Diabetes and Metabolism at Children’s Hospital Los Angeles, as well as chair of the National Diabetes Education Program.

RELATED: Roche, Senseonics extend diabetes monitor distribution deal to BRIC countries

She is also a distinguished professor emerita of pediatrics and communications at the Keck School of Medicine and the Annenberg School of Communications of the University of Southern California, and has served as an adviser to the governor of California on health, fitness and obesity. At Medtronic Diabetes, she also served as VP of global clinical, regulatory and medical affairs, and was elected to the National Academy of Medicine.

“I am very excited to join the Senseonics team, especially at this point where I feel I have an opportunity to help lay the foundation for the first long-term implantable continuous glucose monitoring system,” Kaufman said.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.